Document Detail

Tumor necrosis factor in advanced gastrointestinal neoplasms. A clinical trial with a focus on haematological effects.
MedLine Citation:
PMID:  14651225     Owner:  NLM     Status:  MEDLINE    
This paper presents the results of the clinical trial with the use of hr TNF-alpha (human recombinant tumor necrosis factor-alpha) in 16 advanced gastrointestinal cancer patients. Hr TNF-alpha was administered intravenously in a short, 30-min infusion. According to authors' previous experiences with daily dose escalation (modified Fibonacci scheme), a daily dose of 150 microg/m2 was established as safe, and was well tolerated by the patients. The treatment consisted of 5-day cycles, repeated six times, every 14 days. Special attention was paid regarding the possible side-effect and safety of hr TNF-alpha administration in men, as many acute and chronic haematological toxicities have been reported. After careful analysis of TNF-alpha side-effects, we did not find any acute haematological complications (e.g. thrombosis, DIC, embolism) in any of the patients. Haemoglobin values and erythrocyte and leucocyte counts gradually decreased during each cycle, with the tendency for spontaneous renewal after the treatment had been completed. No cases of thrombocytopenia and severe neuropenia were observed.
M Muc-Wierzgoń; M Baranowski; K Madej
Related Documents :
16678955 - Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted ...
8227305 - Immune activation in myasthenia gravis: soluble interleukin-2 receptor, interferon-gamm...
12358255 - High serum tumor necrosis factor-alpha levels are associated with lack of response to i...
10880265 - High cytosolic pool of p75 tnf receptors and delayed surface downmodulation by mononucl...
21788995 - Inhibition of oestrogen biosynthesis induces mild anxiety in c57bl/6j ovariectomized fe...
8199855 - Cholera toxin-induced gs alpha down-regulation in neural tissue: studies on the pineal ...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article    
Journal Detail:
Title:  Haematologia     Volume:  27     ISSN:  0017-6559     ISO Abbreviation:  Haematologia (Budap)     Publication Date:  1996  
Date Detail:
Created Date:  2003-12-03     Completed Date:  2004-01-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0130266     Medline TA:  Haematologia (Budap)     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  85-92     Citation Subset:  IM    
5-th Department of Internal Diseases, Silesian Medical Academy, Bytom, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Blood Cell Count
Carcinoma / blood,  drug therapy*
Colorectal Neoplasms / blood,  drug therapy
Hematologic Diseases / chemically induced
Immunologic Factors / adverse effects,  therapeutic use*
Middle Aged
Pancreatic Neoplasms / blood,  drug therapy*
Recombinant Proteins / administration & dosage,  adverse effects,  therapeutic use
Stomach Neoplasms / blood,  drug therapy
Treatment Outcome
Tumor Necrosis Factor-alpha / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Immunologic Factors; 0/Recombinant Proteins; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in...
Next Document:  Mitoxantrone and cytosine arabinoside in previously untreated adult patients with acute non-lymphocy...